Treatment Of Coenzyme Q10 For 24 weeks Improves Lipid And Glycemic Profile In Dyslipidemic Individuals

Effect Increase
Values HOMA-IR. Mean and SD. Placebo: before 2.95 (1.49), after 2.76 (1.57). Intervention: before 2.45 (2.22), after 1.52 (0.69).
Trial Design Randomized trial
Trial Length 6+ Months
Number of Subjects 101
Sex Both Genders
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 101 dyslipidemic participants were allocated to take 120 mg of coenzyme q10 daily or placebo for 24 weeks.

The primary outcomes of the trial were the changes in triglycerides, total cholesterol, LDL-c, and HDL-c. There were no statistically significant differences for HDL or total cholesterol, but LDL and triglycerides were significantly reduced compared with placebo. There was also a significantly greater increase in ApoA-I and no difference for ApoB.

Fasting glucose was reduced significantly more in the intervention group, and insulin and HOMA-IR were nonsignificantly reduced. Blood pressure was nonsignificantly reduced more, while there wasn't a notable difference in the change in body weight.

Full details on all 4 studies are available to Examine Plus members.

Already a member? Login now to access.